CAV1 and Parkinson disease: This leads to the inhibition of caveolin-1 degradation via the proteasome-dependent pathway, resulting in an imbalanced cholesterol level, the alteration of membrane fluidity, and dysfunctional lipid raft-dependent endocytosis, which ultimately contribute to PD [256].